August 15, 2019 | Lucas Dan
IntegriChain is utilizing AI and machine learning to develop risk score models that will allow Field Reimbursement Managers (FRMs) and similar functions to proactively intervene on behalf of patients who are likely to experience roadblocks in their journey -- before the roadblocks occur. Predictive patient journey analytics look at analog patient cases and outcomes to understand the likelihood of a new referral experiencing an issue such as lengthy time stalled in prior authorization and appeal. These actionable insights allow an FRM to prioritize potentially challenging patient cases and work to resolve the anticipated roadblock.
Read More
Tags: Field Reimbursement, Fill Rate, Machine learning, patient journey, Patient Journey Analytics, Patient Risk Score, Patient Services, Predictive Analytics, Specialty Patient Status Data, Time to First Fill
July 12, 2019 | Brandon Underwood
The quality of status and sub-status data reported by SPs is an ongoing challenge that limits the actionability of data specialty brands have contracted to receive. Clearly, poor data quality limits the level of insights that analytics can surface for key stakeholders. Simply cleansing and stewarding Cancellation reasons unlocks tremendous value in understanding why patients are abandoning scripts.
Read More
Tags: Canellations, Field Reimbursement, Fill Rate, patient journey, Patient Journey Analytics, Patient Services, Specialty Patient Status Data, Time to First Fill
February 7, 2019 | Brandon Underwood
Without visibility into each individual patient journey, your specialty brand cannot consistently intervene to help patients overcome barriers to therapy initiation and adherence. Today, the poor quality of specialty patient status data is making it impossible to calculate accurate KPI metrics and uncover true patient journey insights. This blog post examines in detail three critical patient status data quality challenges and recommends solutions your specialty brand can implement to overcome these challenges, and ultimately, help patients start therapy faster and stay on therapy longer.
Read More
Tags: patient journey, Patient Journey Analytics, Patient Journey Modeling, Specialty Data Aggregation, Specialty Patient Status Data
December 12, 2018 | Gary Palgon
In this post IntegriChain Senior Vice President of Sales, Gary Palgon, shares the trending topic's from the 2018 CBI Life Sciences Trade & Channel conference held in Philadelphia, Pa December 11-12.
Read More
Tags: patient journey, specialty data strategies, Specialty Pharmacy
December 10, 2018 | Brandon Underwood
An effective specialty data contracting strategy starts at the finish line and works backward. The decisions made in terms of data fields, sub-status granularity, reporting frequency, and contact language, determine the metric outputs that are possible. This post looks at how the right specialty data contracting decisions enable diagnostic patient journey insights that help specialty brands save patient days of therapy.
Read More
Tags: patient journey, Patient Journey Analytics, Specialty Data Aggregation, Specialty Data Contracting, Specialty Patient Status Data
September 26, 2018 | Brandon Underwood
The 340B program is subject to increasing scrutiny as pharmaceutical manufacturers search for solutions to identify and act on non-compliance such as diversion and duplicate discounts. This post is taken from the Q&A session of IntegriChain's recent 340B webinar. Topics discussed include growth in contract pharmacies/covered entities, 340B discount pricing for orphan drugs, and validation of 340B entities.
Read More
Tags: 340B, 867, contract pharmacy, covered entity, Diversion, Duplicate Discounts, Enriched 867 Data, National data, Orphan Drugs, Subnational data
August 20, 2018 | Shivani Patel
The American opioid crisis exposed gaps in the reporting systems designed to flag suspicious orders of pharmaceutical products classified as controlled substances. Pharmaceutical manufacturers are now facing increased scrutiny and need new approaches to monitor and report on irregular order patterns for controlled substances. This post discusses a new approach that provides visibility across pharmacy locations and wholesale distributors while weaving in additional demographic insights.
Read More
Tags: chargebacks, Controlled Substances, Enriched 867 Data, Opioid Crisis, SOMS, Suspicious Order Monitoring
August 3, 2018 | Sean McCarthy
There are several ways specialty brands can improve patient initiation by implementing data-driven patient support strategies. Successful interventions to streamline patient initiation have the potential to speed Time to First Fill and increase overall Fill Rate for new patient referrals. Each key opportunity to improve patient initiation is related to a friction point in the patient journey. In this post, IntegriChain Patient Access Segment Leader Sean McCarthy provides an overview of these key opportunities and the potential of analytics to unlock efficiencies for specialty brands.
Read More
Tags: Bridge Program, Forced Transfers, Patient initiation, patient journey, Prior Authorization, Specialty Pharmacy, Time to Fill
July 27, 2018 | David Carlson
Rare diseases affect 30 million people in the United States, which roughly equates to 10% of the population. In 2017, 40% of the novel drugs approved by the FDA were designated to treat a rare disease. As approvals for rare disease treatments increase, these products account for an ever increasing share of overall pharmaceutical sales. The Payer community is reaching for value as per patient costs rise. This post discusses value-based contracts as a mutually beneficial solution for Payers and pharmaceutical manufacturers and the meaningful role analytics can play in executing and managing these innovative agreements.
Read More
Tags: Commercial Contracting, Managed Markets, Market Access, Orphan Drugs, Payer Contract Strategy, Rare Disease
March 21, 2017 | Brandon Underwood
Brandon Underwood offers a sneak peek at IntegriChain's upcoming Specialty Analytics benchmark report. IntegriChain examined the quality and granularity of status/sub-status data across 40 specialty pharmacies representing different classes of trade (small independent, mid-sized payer, large PBM, etc.). The records we combed through included 15 specialty brands in five therapeutic categories: Immunology, Hematology, Virology, Oncology, and Pulmonary/Respiratory. Overall, IntegriChain and ProMetrics analyzed more than 657,000 sub-status records reported in Q4 2016. The brands we studied had comparable status/sub-status reporting requirements.
Read More
Tags: benchmark report, data confidence, patient journey, Specialty Pharmacy
